Indeed, Tommasi et al. reported the possibility of considering the overexpression of PARP1 and miR-151-5p as predictive biomarkers, useful to correctly select sporadic breast cancers for treatment with PARP inhibitors. The gene discussed is PARP1; the disease is breast carcinoma.